Screening and Prostate-Cancer Mortality in a Randomized European Study

Fritz H. Schröder; Jonas Hugosson; Monique J. Roobol; Teuvo L.J. Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H. Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; B. G. Blijenberg; Sue M. Moss; Harry J. de Koning; Anssi Auvinen

doi:10.1056/nejmoa0810084

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schröder et al. (2009) studied this question.

synapsesocial.com/papers/69dbd2bff7e0c66ced83666c https://doi.org/10.1056/nejmoa0810084

View Full Paper

Ask AI

Bookmark

Share

Screening and Prostate-Cancer Mortality in a Randomized European Study

Ask about this paper

Abstract

Discussion

Cite This Study

Screening and Prostate-Cancer Mortality in a Randomized European Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading